Ãric Vigneault

List of Publications by Year
in descending order

52	1,519	394390	302107
papers	citations	19 h-index	39 g-index

52	52	52	1743
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Randomized Trial of Antioxidant Vitamins to Prevent Acute Adverse Effects of Radiation Therapy in Head and Neck Cancer Patients. Journal of Clinical Oncology, 2005, 23, 5805-5813.	1.6	242
2	A Randomized Trial of Antioxidant Vitamins to Prevent Second Primary Cancers in Head and Neck Cancer Patients. Journal of the National Cancer Institute, 2005, 97, 481-488.	6.3	209
3	Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer. JAMA Oncology, 2015, 1, 1261.	7.1	94
4	Is single fraction 15Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer?. Radiotherapy and Oncology, 2011, 100, 463-467.	0.6	84
5	The 2014 CUA-CUOG Guidelines for the Management of Castration Resistant Prostate Cancer (CRPC). Canadian Urological Association Journal, 2015, 9, 90.	0.6	82
6	An Eight-Year Experience of HDR Brachytherapy Boost for Localized Prostate Cancer: Biopsy and PSA Outcome. International Journal of Radiation Oncology Biology Physics, 2009, 73, 679-684.	0.8	77
7	Postimplant Dosimetry Using a Monte Carlo Dose Calculation Engine: A New Clinical Standard. International Journal of Radiation Oncology Biology Physics, 2007, 68, 1190-1198.	0.8	69
8	Early clinical experience with anatomy-based inverse planning dose optimization for high-dose-rate boost of the prostate. International Journal of Radiation Oncology Biology Physics, 2002, 54, 86-100.	0.8	67
9	Psychological Functioning Associated with Prostate Cancer: Cross-Sectional Comparison of Patients Treated with Radiotherapy, Brachytherapy, or Surgery. Journal of Pain and Symptom Management, 2005, 30, 474-484.	1.2	67
10	Permanent prostate implant using high activity seeds and inverse planning with fast simulated annealing algorithm: A 12-year Canadian experience. International Journal of Radiation Oncology Biology Physics, 2007, 67, 334-341.	0.8	52
11	Treatment options for localized prostate cancer. Canadian Family Physician, 2013, 59, 1269-74.	0.4	37
12	The prostate cancer risk stratification (ProCaRS) project: Recursive partitioning risk stratification analysis. Radiotherapy and Oncology, 2013, 109, 204-210.	0.6	34
13	Bypassing the learning curve in permanent seed implants using state-of-the-art technology. International Journal of Radiation Oncology Biology Physics, 2007, 67, 71-77.	0.8	32
14	Performing daily prostate targeting with a standard V-EPID and an automated radio-opaque marker detection algorithm. Radiotherapy and Oncology, 2004, 73, 61-64.	0.6	31
15	Inverse-planned gynecologic high-dose-rate interstitial brachytherapy: Clinical outcomes and doseâ€“volume histogram analysis. Brachytherapy, 2012, 11, 181-191.	0.5	31
16	High-dose-rate brachytherapy boost for prostate cancer treatment: Different combinations of hypofractionated regimens and clinical outcomes. Radiotherapy and Oncology, 2017, 124, 49-55.	0.6	31
17	Anatomy-based inverse planning dose optimization in HDR prostate implant: A toxicity study. Radiotherapy and Oncology, 2005, 75, 318-324.	0.6	26
18	Prostatic edema in I125 permanent prostate implants: Dynamical dosimetry taking volume changes into account. Medical Physics, 2006, 33, 574-583.	3.0	22

#	Article	IF	Citations
19	Toxicity report of once weekly radiation therapy for low-risk prostate adenocarcinoma: preliminary results of a phase I/II trial. Radiation Oncology, 2011, 6, 112.	2.7	22
20	Canadian Prostate Brachytherapy in 2012. Canadian Urological Association Journal, 2013, 7, 51.	0.6	19
21	Image-guided high-dose-rate brachytherapy boost to the dominant intraprostatic lesion using multiparametric magnetic resonance imaging including spectroscopy: Results of a prospective study. Brachytherapy, 2016, 15, 746-751.	0.5	19
22	Calcifications in low-dose rate prostate seed brachytherapy treatment: Post-planning dosimetry and predictive factors. Radiotherapy and Oncology, 2015, 114, 339-344.	0.6	18
23	Large-scale Retrospective Monte Carlo Dosimetric Study for Permanent Implant Prostate Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2017, 97, 606-615.	0.8	18
24	Randomized non-inferiority trial of Bicalutamide and Dutasteride versus LHRH agonists for prostate volume reduction prior to I-125 permanent implant brachytherapy for prostate cancer. Radiotherapy and Oncology, 2016, 118, 141-147.	0.6	16
25	Long-Term Results of NRG Oncology/RTOG 0321: A Phase II Trial of Combined High Dose Rate Brachytherapy and External Beam Radiation Therapy for Adenocarcinoma of the Prostate. International Journal of Radiation Oncology Biology Physics, 2021, 110, 700-707.	0.8	13
26	Retrospective study of 81 patients treated with brachytherapy for endobronchial primary tumor or metastasis. Brachytherapy, 2010, 9, 243-247.	0.5	12
27	The Prostate Cancer Risk Stratification Project: Database Construction and Risk Stratification Outcome Analysis. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 60-69.	4.9	12
28	Impact of a dominant intraprostatic lesion (DIL) boost defined by sextant biopsy in permanent I-125 prostate implants on biochemical disease free survival (bDFS) and toxicity outcomes. Radiotherapy and Oncology, 2019, 133, 62-67.	0.6	12
29	Evaluating the impact of real-time multicriteria optimizers integrated with interactive plan navigation tools for HDR brachytherapy. Brachytherapy, 2020, 19, 607-617.	0.5	10
30	Monte Carlo dosimetry of high dose rate gynecologic interstitial brachytherapy. Radiotherapy and Oncology, 2013, 109, 425-429.	0.6	9
31	Idealized line source configuration for permanent 125I prostate implants. Radiotherapy and Oncology, 2004, 72, 213-220.	0.6	8
32	Multicenter Evaluation of Biochemical Relapseâ€“Free Survival Outcomes for Intraoperatively Planned Prostate Brachytherapy Using an Automated Delivery System. International Journal of Radiation Oncology Biology Physics, 2017, 99, 895-903.	0.8	8
33	Coupling Iâ€125 permanent implant prostate brachytherapy Monte Carlo dose calculations with radiobiological models. Medical Physics, 2017, 44, 4329-4340.	3.0	6
34	Does prostate volume has an impact on biochemical failure in patients with localized prostate cancer treated with HDR boost?. Radiotherapy and Oncology, 2016, 121, 304-309.	0.6	5
35	The association of intraprostatic calcifications and dosimetry parameters with biochemical control after permanent prostate implant. Brachytherapy, 2019, 18, 787-792.	0.5	5
36	A genome-wide association study of non-HPV-related head and neck squamous cell carcinoma identifies prognostic genetic sequence variants in the MAP-kinase and hormone pathways. Cancer Epidemiology, 2016, 42, 173-180.	1.9	4

#	Article	IF	Citations
37	Inter-observer evaluation of a GPU-based multicriteria optimization algorithm combined with plan navigation tools for HDR brachytherapy. Brachytherapy, 2022, 21, 551-560.	0.5	4
38	A Comparison of Treatment Outcomes by Radiochemotherapy and Postoperative Radiotherapy in Locally Advanced Squamous Cell Carcinomas of Head and Neck. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 379-383.	1.3	3
39	Management of Bartholinâ€™s gland carcinoma using high-dose-rate interstitial brachytherapy boost. Brachytherapy, 2013, 12, 500-507.	0.5	3
40	75 Permanent prostate implants and acute urinary obstruction: A multivariate analysis on edema and dosimetric parameters. Radiotherapy and Oncology, 2000, 55, 45-46.	0.6	2
41	High-Dose-Rate Interstitial Brachytherapy in the Management ofÂCarcinoma of The Bartholin Gland: A Single Institution Experience with Long-Term Followup. Brachytherapy, 2010, 9, S87-S88.	0.5	2
42	High-dose-rate prostate brachytherapy and supplemental external beam radiotherapy: A comparison of single fraction 15Gy high-dose-rate and hypofractionated external beam to a conventional fractionated regimen. Brachytherapy, 2009, 8, 110.	0.5	1
43	Clinical Outcomes in Patients Treated with Selective HDR Image-Guided Boost to Dominant Intra-Prostatic Lesion. Brachytherapy, 2016, 15, S52.	0.5	1
44	A multicentric Phase II study of high-dose-rate brachytherapy boost in combination with external beam radiotherapy in patients with intermediate-risk carcinoma of the prostate. Brachytherapy, 2007, 6, 87.	0.5	0
45	Impact of intraoperative treatment planning on clinical outcomes in I-125 prostate brachytherapy. Brachytherapy, 2007, 6, 107.	0.5	0
46	Impact of intraoperative technology on seed migration for loose seed prostate implants. Brachytherapy, 2008, 7, 167.	0.5	0
47	Acute and Late Toxicity in Patients Treated with Selective High-Dose-Rate Image-Guided Boost to Dominant Intraprostatic Lesion. Brachytherapy, 2013, 12, S33-S34.	0.5	0
48	Impact of Technology and Learning Curve on Migration and Seed Loss in Permanent Prostate Implants. Brachytherapy, 2014, 13, S70-S71.	0.5	0
49	Real-Time EM-Tracking Based Treatment Platform for High Dose Rate Prostate Brachytherapy: End-to-End Validation and Clinical Workflows. Brachytherapy, 2016, 15, S38-S39.	0.5	0
50	32: Multicentre Canadian Experience using Intraoperative Prostate Brachytherapy for Treatment of Low and Intermediate-Risk Prostate Cancer; an Evaluation of Long-Term Biochemical Relapse-Free Survival Outcomes. Radiotherapy and Oncology, 2016, 120, S12.	0.6	0
51	141: Validation of a French Canadian Version of the Expanded Prostate Cancer Index Composite Instrument (EPIC). Radiotherapy and Oncology, 2016, 120, S52-S53.	0.6	0
52	Effect of Different Hypofractionated Regimens Combination on Clinical Outcomes in Prostate Cancer Patients Treated with High Dose-Rate Brachytherapy Boost. Brachytherapy, 2017, 16, S54-S55.	0.5	0